Protalix BioTherapeutics, Inc.
AMEXProtalix BioTherapeutics arrives at its Q1 results day with a dramatic revenue beat already on the tape — yet the stock's month-long slide and a sharp defensive tilt in options suggest the market is still far from convinced. Q1 revenue came in at $33.75M, demolishing the Street's $11.47M estimate. The headline driver was a $25M Elfabrio milestone payment that pulled the quarter's…
Snapshot as of 30 May 2026
Protalix BioTherapeutics arrives at its Q1 results day with a dramatic revenue beat already on the tape — yet the stock's month-long slide and a sharp defensive tilt in options suggest the market is still far from…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PLX — free to start on ORTEX.
Sign up for free →Open PLX on ORTEX